Surrey Heartlands

Joint Formulary & PAD

Desmopressin acetate - Nocturnal polyuria

You are here : Home > Formulary Search > Desmopressin acetate - Nocturnal polyuria

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral lyophilisates
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

Initiation and 1 month supply by the specialist before any request for primary care prescribing.

Women - 25mcg dose

Men - 50mcg dose

Documentation

Guidelines (Local)
Nocturia - Treatment pathway- April 2019.pdf
Evidence Review
Desmopressin (Noqdirna) for nocturnal polyuria - DTC evaluation - April 2019.pdf

PAD Profile

ChemicalSubstance :
Desmopressin acetate
Indication :
Nocturnal polyuria
Group Name :
Keywords :
vasopressin analogue, LUTS, nocturia
Brand Names Include :
Noqdirna
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Desmopressin acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Nocturnal polyuria.

  • No records returned.

Committee Recommendations (1)

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee (APC) recommends desmopressin (Noqdirna) as a treatment option for idiopathic noturnal polyuria.

Desmopressin (Noqdirna) is a licensed product and should be prescibed as an alternative to other, off label desmopressin preparations.

Desmopressin (Noqdirna) will be assigned a BLUE (no information sheet) traffic light status and specialists in secondary care will be required to prescribe at least 1 month of desmopressin prior to requesting transfer of care with the patients primary care provider.

The attached nocturia treatment pathway has been developed in conjunction with colleagues at Ashford & St Peters Hospitals NHS Foundation Trust and is expected to compliment the information all ready available for prescribers on this page. See below for further information